Proteasome inhibition overcomes TRAIL resistance in human hepatoblastoma cells

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 6, 2012, Pages 2194-22012

  Armeanu Ebinger, Sorin ^a   Fuchs, Joerg ^a   Wenz, Julia ^a   Seitz, Guido ^a   Ruck, Peter ^b   Warmann, Steven W ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Krankenhaus Leonberg   (Germany)

Author keywords

Hepatoblastoma; Proteasome inhibitors; TRAIL; TRAIL resistance

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALPHA FETOPROTEIN; BORTEZOMIB; CARBOPLATIN; CASPASE 3; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALPHA FETOPROTEIN BLOOD LEVEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MEGADOSE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; PRESCHOOL CHILD; PROTEIN EXPRESSION; RECEPTOR BLOCKING; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84860851054     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e536     Document Type: Article

References (41)

1. S. Armeanu, M. Krusch, K.M. Baltz, T.S. Weiss, I. Smirnow, A. Steinle, U.M. Lauer, M. Bitzer& H.R. Salih: Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res 14, 3520-3528 (2008))
2. M. Bagnoli, S. Canevari& D. Mezzanzanica: Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 42, 210-213 (2010))
3. K.F. Chen, P.Y. Yeh, C. Hsu, C.H. Hsu, Y.S. Lu, H.P. Hsieh, P.J. Chen& A.L. Cheng: Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284, 11121-11133 (2009))
4. T.N. Chonghaile, A. Letai: Mimicking the BH3 domain to kill cancer cells. Oncogene 27 Suppl 1, S149-S157 (2008))
5. E.C. Dees, B.H. O'Neil, C.M. Lindley, F. Collichio, L.A. Carey, J. Collins, W.J. Riordan, A. Ivanova, D. Esseltine& R.Z. Orlowski: A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63, 99-107 (2008))
6. Q.L. Deveraux, R. Takahashi, G.S. Salvesen& J.C. Reed: X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300-304 (1997)) (Pubitemid 27317977)
7. I. Doi, Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 67, 1-10 (1976))
8. X. Du, G. Bao, X. He, H. Zhao, F. Yu, Q. Qiao, J. Lu& Q. Ma: Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res 28, 24 (2009))
9. J. Dzieran, J.F. Beck& J. Sonnemann: Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics. Cancer Sci 99, 1685-1692 (2008))
10. I. Fabregat: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15, 513-520 (2009))
11. C. Falschlehner, U. Schaefer& H. Walczak: Following TRAIL's path in the immune system. Immunology 127, 145-154 (2009))
12. J. Fuchs, J. Rydzynski, S.D. Von, U. Bode, H. Hecker, P. Weinel, D. Burger, D. Harms, R. Erttmann, K. Oldhafer& H. Mildenberger: Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 95, 172-182 (2002)) (Pubitemid 34743496)
13. P. Gimenez-Bonafe, A. Tortosa& R. Perez-Tomas: Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 9, 320-340 (2009))
14. D. Herrmann, G. Seitz, S.W. Warmann, M. bonin, J. Fuchs& S. Armeanu-Ebinger: Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro. J Immunotherapy 33, 279-286 (2010))
15. P.A. Holoch, T.S. Griffith: TNF-related apoptosisinducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 625, 63-72 (2009))
16. S. Huang, F.A. Sinicrope: BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 68, 2944-2951 (2008)) (Pubitemid 351556295)
17. M. Irmler, M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L.E. French& J. Tschopp: Inhibition of death receptor signals by cellular FLIP. Nature 388, 190-195 (1997)) (Pubitemid 27297457)
18. M. Ishii, M. Iwai, Y. Harada, T. Kishida, H. Asada, M. Shin-Ya, Y. Itoh, J. Imanishi, T. Okanoue& O. Mazda: Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Lett 245, 134-143 (2007)) (Pubitemid 44959347)
19. D.D. Jandial, S. Farshchi-Heydari, C.A. Larson, G.I. Elliott, W.J. Wrasidlo& S.B. Howell: Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15, 553-560 (2009))
20. M.H. Kang, C.P. Reynolds: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15, 1126-1132 (2009))
21. V. Kirkin, S. Joos& M. Zornig: The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644, 229-249 (2004)) (Pubitemid 38281277)
22. B.C. Koehler, T. Urbanik, B. Vick, R.J. Boger, S. Heeger, P.R. Galle, M. Schuchmann& H. Schulze-Bergkamen: TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 15, 5924-5935 (2009))
23. M. Lauricella, S. Emanuele, A. D'Anneo, G. Calvaruso, B. Vassallo, D. Carlisi, P. Portanova, R. Vento& G. Tesoriere: JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis 11, 607-625 (2006))
24. S. Leong, R.B. Cohen, D.L. Gustafson, C.J. Langer, D.R. Camidge, K. Padavic, L. Gore, M. Smith, L.Q. Chow, M.M. von, C. O'Bryant, S. Hariharan, S. Diab, N.L. Fox, R. Miceli& S.G. Eckhardt: Mapatumumab, an antibody targeting TRAILR1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 27, 4413-4421 (2009))
25. J. Lieber, B. Kirchner, C. Eicher, S.W. Warmann, G. Seitz, J. Fuchs& S. Armeanu-Ebinger: Inhibition of Bcl-2 and Bcl-X enhances chemotherapy effects in hepatoblastoma cells. Pediatric Blood and Cancer in press, (2010))
26. J.J. Marin, M.R. Romero, P. Martinez-Becerra, E. Herraez& O. Briz: Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 9, 1108-1129 (2009))
27. D.J. McConkey, K. Zhu: Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11, 164-179 (2008))
28. O. Ndozangue-Touriguine, M. Sebbagh, D. Merino, O. Micheau, J. Bertoglio& J. Breard: A mitochondrial block and expression of XIAP lead to resistance to TRAILinduced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27, 6012-6022 (2008))
29. A. Pathil, S. Armeanu, S. Venturelli, P. Mascagni, T.S. Weiss, M. Gregor, U.M. Lauer& M. Bitzer: HDAC inhibitor treatment of hepatoma cells induces both TRAILindependent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43, 425-434 (2006))
30. G. Perilongo, R. Maibach, E. Shafford, L. Brugieres, P. Brock, B. Morland, C.B. de, J. Zsiros, D. Roebuck, A. Zimmermann, D. Aronson, M. Childs, E. Widing, V. Laithier, J. Plaschkes, J. Pritchard, M. Scopinaro, G. MacKinlay& P. Czauderna: Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361, 1662-1670 (2009))
31. G. Perilongo, E. Shafford, R. Maibach, D. Aronson, L. Brugieres, P. Brock, M. Childs, P. Czauderna, G. MacKinlay, J.B. Otte, J. Pritchard, R. Rondelli, M. Scopinaro, C. Staalman& J. Plaschkes: Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer 40, 411-421 (2004)) (Pubitemid 38121279)
32. T. Pietsch, C. Fonatsch, S. Albrecht, H. Maschek, H.K. Wolf& S.D. Von: Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 74, 809-818 (1996)) (Pubitemid 26117140)
33. N. Roy, Q.L. Deveraux, R. Takahashi, G.S. Salvesen& J.C. Reed: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16, 6914-6925 (1997)) (Pubitemid 27520792)
34. A.R. Safa, T.W. Day& C.H. Wu: Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8, 37-46 (2008)) (Pubitemid 351237908)
35. H. Schulze-Bergkamen, A. Weinmann, M. Moehler, J. Siebler& P.R. Galle: Novel ways to sensitise gastrointestinal cancer to apoptosis. Gut 58, 1010-1024 (2009))
36. J.H. Song, K. Kandasamy& A.S. Kraft: ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 283, 25003-25013 (2008))
37. I. Tamm, Y. Wang, E. Sausville, D.A. Scudiero, N. Vigna, T. Oltersdorf& J.C. Reed: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58, 5315-5320 (1998)) (Pubitemid 28551107)
38. M.L. Tan, J.P. Ooi, N. Ismail, A.I. Moad& T.S. Muhammad: Programmed cell death pathways and current antitumor targets. Pharm Res 26, 1547-1560 (2009))
39. S.W. Warmann, S. Armeanu, H. Heigoldt, P. Ruck, R. Vonthein, H. Heitmann, G. Seitz, M.L. Lemken, M. Bitzer, J. Fuchs& U.M. Lauer: Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer 53, 145-151 (2009))
40. S.W. Warmann, H. Frank, H. Heitmann, P. Ruck, T. Herberts, G. Seitz& J. Fuchs: Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 144, 43-48 (2008)) (Pubitemid 350234956)
41. A. Zimmermann, The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer 41, 1503-1514 (2005)) (Pubitemid 40981831)